Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023

Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its first quarter financial results on May 3, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET the same day. Participants may pre-register for Q&A via telephone to receive dial-in details. The event will also be available as a live webcast. Pacira focuses on non-opioid pain management solutions and offers three commercial products: EXPAREL®, ZILRETTA®, and ioveraº®. These innovative interventions aim to reduce dependence on opioids and address various pain-related conditions.

Positive

• The company is committed to providing non-opioid alternatives, which may attract more patients and increase market share.
• Pacira has three commercial products, showcasing a diversified product portfolio in pain management.

Negative

• None.

TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

FAQ

When will Pacira BioSciences report its first quarter financial results?

Pacira BioSciences will report its first quarter financial results on May 3, 2023.

What time is the conference call for Pacira's financial results?

The conference call is scheduled for 8:30 a.m. ET on May 3, 2023.

How can I participate in the Q&A session during Pacira's conference call?

To participate in the Q&A session, listeners must pre-register to receive dial-in information and a PIN.

What are the main products offered by Pacira BioSciences?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® as part of its non-opioid pain management solutions.

Where can I access the replay of Pacira's conference call?

The replay of Pacira's conference call will be available on their website for approximately two weeks after the event.